Elevated Expression of the RNA-Binding Protein IGF2BP1 Enhances the Mrna Stability and Translation Efficiency of INHBA to Promote the Invasion and Migration of Esophageal Squamous Cancer Cells

Sheng Wang, Ding-Xiong Chen, Yu Zhang, Yan Cai, Xin Xu, Jia‐Jie Hao, Ming‐Rong WangResearch 2021 · DOI

Introduction

Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy characterized by early metastasis and a poor five-year survival rate of approximately 30%. While transcriptional changes are well-documented, the role of post-transcriptional regulators—specifically RNA-binding proteins (RBPs)—in driving ESCC progression is less understood. IGF2BP1 (Insulin-like growth factor 2 mRNA-binding protein 1) is an oncofetal protein typically active during development but silenced in adults. Its aberrant "re-awakening" in various cancers suggests a potent role in oncogenesis. This study investigates how IGF2BP1 orchestrates the invasive phenotype of ESCC by regulating the stability and translation of specific target mRNAs.

Methods

The researchers employed a multi-disciplinary approach to elucidate the role of IGF2BP1:

  • Clinical Validation: Protein and mRNA levels were assessed in 311 ESCC patient samples using immunohistochemistry (IHC) and RNA in situ hybridization (RISH), supplemented by data from The Cancer Genome Atlas (TCGA-ESCA).
  • Functional Assays: CRISPR/Cas9 and siRNA-mediated knockdown, alongside plasmid-based overexpression, were used in ESCC cell lines (KYSE30, TE1) to evaluate migration, invasion, and in vivo metastasis in mouse models.
  • Mechanistic Discovery: RNA Immunoprecipitation sequencing (RIP-seq) identified direct mRNA targets, while mass spectrometry (Co-IP MS) identified protein partners. RNA stability was measured via Actinomycin D assays, and promoter methylation was analyzed using methylation-specific PCR (MSP-PCR).

Results

IGF2BP1 Overexpression and Clinical Correlation

IGF2BP1 was found to be highly expressed in 49.8% of ESCC tissues, while remaining virtually undetectable in adjacent normal esophageal tissue. High expression levels significantly correlated with the depth of tumor invasion ($P = 0.024$), identifying IGF2BP1 as a potential biomarker for aggressive disease. Functional assays demonstrated that silencing IGF2BP1 markedly reduced the migratory and invasive capabilities of ESCC cells and significantly inhibited lung metastasis in vivo.

The IGF2BP1-INHBA Axis and $m^6A$ Recognition

RIP-seq identified INHBA (Inhibin Beta A) as a primary downstream target of IGF2BP1. IGF2BP1 acts as a "reader" for $m^6A$ (N6-methyladenosine) modifications on INHBA mRNA. By binding to these sites, IGF2BP1 protects INHBA mRNA from degradation, increasing its half-life from 3.6 to 4.7 hours in KYSE30 cells. Furthermore, the study revealed that IGF2BP1 recruits G3BP1 (G3BP stress granule assembly factor 1) to form a complex that enhances the translation efficiency of INHBA, leading to significantly higher protein levels.

Activation of Smad2/3 Signaling

The upregulation of INHBA protein activates the TGF-β/Smad2/3 signaling pathway, promoting the epithelial-mesenchymal transition (EMT) necessary for metastasis. Silencing the IGF2BP1-INHBA axis or using the small molecule inhibitor BTYNB effectively suppressed Smad2/3 activation and attenuated the malignant phenotypes of ESCC cells.

Epigenetic Drivers of IGF2BP1 Expression

The study also addressed the cause of IGF2BP1 overexpression. Methylation-specific PCR indicated that the IGF2BP1 promoter region is frequently hypomethylated in ESCC cells compared to normal cells. This loss of chemical silencing marks allows for the aberrant re-expression of this fetal protein in the adult esophageal environment.

Conclusion

This research identifies IGF2BP1 as a master post-transcriptional regulator in ESCC. By stabilizing INHBA mRNA and enhancing its translation through a partnership with G3BP1, IGF2BP1 drives the Smad2/3-mediated invasive program. These findings highlight the IGF2BP1/INHBA/Smad axis as a promising therapeutic target for patients with aggressive ESCC.

Summary updated

Abstract

Abstract Background: The mechanisms underlying the occurrence and development of esophageal squamous cell carcinoma (ESCC) remains to be elucidated. The present study aims to investigate the roles and implications of IGF2BP1 overexpression in ESCC. Methods: IGF2BP1 protein expression in ESCC samples was assessed by immunohistochemistry (IHC), and the mRNA abundance of IGF2BP1 and INHBA was analyzed with TCGA datasets and by RNA in situ hybridization (RISH). Cell viability, migration, invasion and in vivo metastasis assays were performed to explore the roles of IGF2BP1 overexpression in ESCC. RNA immunoprecipitation sequencing (RIP-seq) and mass spectrometry were applied to identify the target RNAs and interacting proteins of IGF2BP1, respectively. RIP-PCR, RNA pulldown, immunofluorescence (IF), gene-specific m 6 A PCR and RNA stability assays were used to uncover the molecular mechanisms underlying the malignant phenotypes of ESCC cells caused by IGF2BP1 dysregulation. The methylation level of the IGF2BP1 promoter region was detected by methylation-specific PCR (MSP-PCR). BTYNB, a small molecular inhibitor was evaluated for its inhibitory effect on the malignant phenotypes of ESCC cells. Results: IGF2BP1 overexpression was detected in ESCC tissues and associated with the depth of tumor invasion. Knockdown of IGF2BP1 inhibited ESCC cell invasion and migration as well as tumor metastasis. Mechanistically, we observed that IGF2BP1 bound and stabilized INHBA mRNA and then enhanced the translation of INHBA, leading to the activation of Smad2/3 signaling, thus promoting malignant phenotypes. The mRNA level of INHBA was upregulated in ESCC tissues as well. Furthermore, IGF2BP1 interacted with G3BP stress granule assembly factor 1 (G3BP1) and activated the INHBA-Smad signaling. BTYNB abolished this activated signaling and significantly attenuated the malignant phenotypes of ESCC cells. In addition, IGF2BP1 mRNA expression in ESCC cells was negatively correlated with the level of its promoter methylation. Conclusions: Elevated expression of IGF2BP1 is a frequent event in ESCC tissues and might be a candidate biomarker for the disease. IGF2BP1 overexpression promotes the invasion and migration of ESCC cells by activating the INHBA-TGF-β-Smad2/3 pathway, providing a potential therapeutic target for ESCC patients with high expression of IGF2BP1.
BibTeX
@inproceedings{wang2021elevated,
  author = {Sheng Wang and Ding-Xiong Chen and Yu Zhang and Yan Cai and Xin Xu and Jia‐Jie Hao and Ming‐Rong Wang},
  title = {{Elevated Expression of the RNA-Binding Protein IGF2BP1 Enhances the Mrna Stability and Translation Efficiency of INHBA to Promote the Invasion and Migration of Esophageal Squamous Cancer Cells}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-885735/v1},
}
Figure